These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

993 related items for PubMed ID: 19637339

  • 1. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.
    Cancer; 2009 Oct 01; 115(19):4470-6. PubMed ID: 19637339
    [Abstract] [Full Text] [Related]

  • 2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D, Tyldesley S, Pickles T, Prostate Cohort Outcomes Initiative.
    Cancer; 2008 May 01; 112(9):1941-8. PubMed ID: 18338814
    [Abstract] [Full Text] [Related]

  • 5. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 01; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 6. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 7. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct 17; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

  • 8. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L.
    Prostate; 2010 May 15; 70(7):718-26. PubMed ID: 20087896
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Cancer; 2008 Mar 15; 112(6):1247-53. PubMed ID: 18293426
    [Abstract] [Full Text] [Related]

  • 10. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML.
    Cancer; 2002 Sep 01; 95(5):1028-36. PubMed ID: 12209687
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D, Cowan J, Carroll P, Konety B.
    BJU Int; 2010 Apr 01; 105(7):951-5. PubMed ID: 19889066
    [Abstract] [Full Text] [Related]

  • 13. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun 01; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 14. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e335-44. PubMed ID: 21645976
    [Abstract] [Full Text] [Related]

  • 15. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
    Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED, Southwest Oncology Group Study.
    Cancer; 2006 Aug 01; 107(3):489-96. PubMed ID: 16804926
    [Abstract] [Full Text] [Related]

  • 16. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ, Barber BL, Markus RA.
    Urology; 2007 Dec 01; 70(6):1104-8. PubMed ID: 18158027
    [Abstract] [Full Text] [Related]

  • 17. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M, Cavalli V, Bravi F.
    BJU Int; 2010 Mar 01; 105(5):648-51. PubMed ID: 19747358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
    Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE).
    Cancer; 2008 Jan 15; 112(2):307-14. PubMed ID: 18050294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.